GLP-1 medications and PCOS: what the evidence actually shows
GLP-1 medicines can help some adults with PCOS manage weight and metabolic risk, but they are not FDA approved to treat PCOS itself.
Read moreThe Patient Intelligence Desk for GLP-1 News, Research, and Access
The next digest is under review
Weekly briefings only appear here after editorial review and public publish. Until the next edition clears, use the archive for recent GLP-1 signal or start with the current patient guides below.
Current headlines
Understanding Wegovy dosing: a clear guide
Wegovy injection starts at 0.25 mg once weekly and increases every four weeks toward a maintenance dose, with label rules for doses that are not tolerated or are missed.
Read moreWhy Insurers Are Dropping or Changing GLP-1 Coverage in 2026
A plain-language breakdown of formulary tightening, prior authorization logic, and what patients are really comparing when cash pay becomes the fallback.
Read moreMost popular
What “Food Noise” Means and Why GLP-1 Patients Keep Using That Phrase
Across GLP-1 communities, patients use “food noise” to describe the chatter around hunger and reward. The phrase persists because it maps onto lived experience better than a clinical label.
Full analysisGLP-1 medications and PCOS: what the evidence actually shows
GLP-1 medicines can help some adults with PCOS manage weight and metabolic risk, but they are not FDA approved to treat PCOS itself.
Full analysisOutside Publications We Track for Obesity, Metabolic Health, and GLP-1 Care
We track over twenty independent publications covering obesity medicine, metabolic health, and GLP-1 treatment. The list includes clinician-scientists, specialist obesity writers, and adjacent medical voices that add context most news sources miss.
Rotating three
Preventive cardiology with cardiometabolic overlap
Danielle Belardo M.D.
Started publishing Mar 2021
Danielle Belardo is most useful when you want weight-loss treatment placed in a broader cardiometabolic frame. The writing connects GLP-1 therapy, preventive cardiology, blood pressure, and lifestyle change in a way that helps readers see how weight care fits into overall risk reduction. It is better as a crossover read than as a dedicated obesity-only source, but that overlap is exactly why it earns a place here.
Evidence-based medicine and policy commentary
Greg Katz, MD
Started publishing Jan 2024
Greg Katz is most useful when the category spills into bigger questions about evidence, policy, or how medicine gets explained in public. He is not writing a specialist obesity newsletter, but he is good at sharpening the way readers think about claims and tradeoffs. This is a solid adjacent read for people who care about the quality of the argument, not just the headline.
Lifestyle medicine and metabolic-health coaching
The Habit Healers
Started publishing Mar 2025
The Habit Healers is useful for readers who want more than medication talk. The writing leans into habits, nutrition, lifestyle medicine, and metabolic health, which makes it a good complement to more drug-heavy coverage. If you want practical context around how treatment fits into daily life, this is a worthwhile crossover read.
What Patients Ask First
Managing Side Effects
Cost + Access
Precision Coverage
Every article, explainer, and company profile is built on named sources, cited research, and structured editorial review. Browse by topic or start with what other readers are finding useful.